NCNA
$4.50
Nucana Plc ADR
$.04
.90%
NCNA
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.21)
Revenue:  $0.00 Mil
Thursday
Feb 18
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NCNA reports earnings?
Beat
Meet
Miss

Where is NCNA's stock price going from here?
Up
Flat
Down
Stock chart of NCNA
Analysts
Summary of analysts' recommendations for NCNA
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company's pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom.